Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 36.33% is 24% above its 5-year average of 29.40%, near the high end of its 5-year range (18.67%–40.10%).
0.41% above its 12-month average of 36.18%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2027 (2026-07-31): 40.10%.
EBITDA MARGIN
36.33%
EBITDA MARGIN AVG TTM
36.18%
EBITDA MARGIN AVG 3Y
32.95%
EBITDA MARGIN AVG 5Y
29.40%
EBITDA MARGIN AVG 10Y
29.81%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.41%
CURRENT VS 3Y AVG
+10.26%
CURRENT VS 5Y AVG
+23.59%
CURRENT VS 10Y AVG
+21.87%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
HealthEquity, Inc.
Market Cap
$7.59B
EBITDA Margin
36.33%
TTM Avg
36.18%
3Y Avg
32.95%
5Y Avg
29.40%
Market Cap
$7.61B
EBITDA Margin
-684.44%
TTM Avg
-1767.79%
3Y Avg
-2575.30%
5Y Avg
-1786.18%
Market Cap
$7.51B
EBITDA Margin
-92.07%
TTM Avg
-49.82%
3Y Avg
-47.83%
5Y Avg
-47.83%
Market Cap
$7.29B
EBITDA Margin
-38.32%
TTM Avg
-51.29%
3Y Avg
-52.67%
5Y Avg
-38.88%
Market Cap
$8.14B
EBITDA Margin
8.34%
TTM Avg
-21.08%
3Y Avg
-58.51%
5Y Avg
-29.82%
Market Cap
$8.39B
EBITDA Margin
-870.12%
TTM Avg
-705.14%
3Y Avg
-488.60%
5Y Avg
-370.00%
Market Cap
$8.47B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HealthEquity, Inc. (HQY) | $7.59B | 36.33% | 36.18% | 32.95% | 29.40% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.61B | -684.44% | -1767.79% | -2575.30% | -1786.18% |
| Hinge Health, Inc. (HNGE)vs › | $7.51B | -92.07% | -49.82% | -47.83% | -47.83% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.29B | -38.32% | -51.29% | -52.67% | -38.88% |
| Caris Life Sciences, Inc. (CAI)vs › | $8.14B | 8.34% | -21.08% | -58.51% | -29.82% |
| Alkermes plc (ALKS)vs › | $6.93B | 19.05% | 23.95% | 20.94% | 15.97% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.39B | -870.12% | -705.14% | -488.60% | -370.00% |
| Oscar Health, Inc. (OSCR)vs › | $8.47B | -3.14% | -1.08% | -5.02% | -19.32% |
| Chemed Corporation (CHE)vs › | $6.67B | 15.93% | 16.80% | 17.55% | 18.41% |
| Immunovant, Inc. (IMVT)vs › | $6.63B | N/A | N/A | N/A | N/A |
Gross Margin
75.2%
EBITDA Margin
36.3%
Operating Margin
25.6%
Net Margin
17.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-07-31 | 40.10% |
| 2026-04-30 | 32.59% |
| 2026-01-31 | 31.70% |
| 2025-10-31 | 36.82% |
| 2025-07-31 | 39.69% |
| 2025-04-30 | 37.21% |
| 2025-01-31 | 35.50% |
| 2024-10-31 | 31.55% |
| 2024-07-31 | 34.78% |
| 2024-04-30 | 28.76% |
| 2024-01-31 | 30.14% |
| 2023-10-31 | 22.77% |
| 2023-07-31 | 26.74% |
| 2023-04-30 | 26.87% |
| 2023-01-31 | 25.15% |
| 2022-10-31 | 24.32% |
| 2022-07-31 | 22.32% |
| 2022-04-30 | 20.17% |
| 2022-01-31 | 18.67% |
| 2021-10-31 | 25.80% |
| 2021-07-31 | 25.67% |
| 2021-04-30 | 24.34% |
| 2021-01-31 | 23.11% |
| 2020-10-31 | 27.36% |
| 2020-07-31 | 27.26% |
| 2020-04-30 | 29.13% |
| 2020-01-31 | 26.22% |
| 2019-10-31 | 29.70% |
| 2019-07-31 | 37.63% |
| 2019-04-30 | 37.28% |
| 2019-01-31 | 28.07% |
| 2018-10-31 | 33.43% |
| 2018-07-31 | 36.53% |
| 2018-04-30 | 35.85% |
| 2018-01-31 | 21.91% |
| 2017-10-31 | 30.94% |
| 2017-07-31 | 35.42% |
| 2017-04-30 | 35.02% |
| 2017-01-31 | 20.99% |
| 2016-10-31 | 28.74% |
| 2016-07-31 | 36.02% |
| 2016-04-30 | 36.80% |
| 2016-01-31 | 14.88% |
| 2015-10-31 | 21.97% |
| 2015-07-31 | 25.93% |
| 2015-04-30 | 28.11% |
| 2015-01-31 | 9.77% |
| 2014-10-31 | 21.51% |
| 2014-07-31 | 26.23% |
| 2014-04-30 | 33.31% |
| 2014-01-31 | 15.84% |
| 2013-10-31 | 29.82% |
| 2013-07-31 | 30.85% |
| 2013-04-30 | 26.71% |
